GE Ventures, the corporate venturing arm of industrial product maker General Electric, and medical research company Mayo Clinic launched a US-based cell and gene data platform called Vitruvian Networks this week.
Vitruvian intends to build a cloud-ready software and manufacturing platform that incorporates business intelligence and data analytics technology to serve gene therapy companies.
The company will initially concentrate on producing autologous cell therapies to treat blood cancers. It will combine Mayo Clinic’s biomarker, cell therapy and clinical outcome data with gene therapy technology from GE division GE Healthcare and plans to utilise resources from other subsidiaries such as GE Aviation and GE Power.
Sue Siegel, chief executive of GE Ventures, said: “Merging GE’s operational excellence with emerging cell and gene therapies will enable faster, more effective and safer treatments for patients.
“Mayo Clinic is a key leader in patient treatment delivery in cancer care and regenerative medicine, so we are honoured to have incubated this solution in joint partnership.”